As a new subsidiary of SightLife, we’re accelerating our shared mission: to eliminate treatable corneal blindness worldwide by 2040. We’re driving innovations in research, products, therapeutics, prevention and policy to transform the corneal ecosystem.
This FREE webinar assists surgeons in the early adoption of DMEK.
To request your copy of “DMEK: Beyond the Learning Curve,” please click the link, below.
We’re committed to leading research efforts and developing new technologies for innovative and affordable therapeutics that will transform the medical care available for those living with corneal blindness.
We’re committed to removing systemic barriers that limit patients’ access to care and surgeons’ ability to provide the best corneal treatments to their patients.
We’re committed to significantly increasing prevention and early treatment solutions, which are critical to eliminating corneal blindness by 2040.